The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors
October 21, 2021
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2022 Officers, Executive Committee, and Board of Directors.
ARM commends FDA for, among other things, the inclusion of two priority elements supported by ARM in the agency’s Prescription Drug User Fee Act VII (PDUFA) commitment letter that will advance cell and gene therapy.
Global Cell & Gene Therapy Sector on Pace for Annual Records in Product Approvals and Financings, Says Alliance for Regenerative Medicine
August 18, 2021
The regenerative medicine and advanced therapies sector completed its best-ever six-month period of financing, raising $14.1B from January through June and reaching 71% of the record amount raised in all of 2020, according to the Alliance for Regenerative Medicine’s (ARM) H1 2021 Report released today.
ARM and NIIMBL Release Project A-Gene to Bring Quality by Design Principles to Gene Therapy Manufacturing
June 24, 2021
The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) today released Project A-Gene, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into a manufacturing case study of a viral vector commonly used in gene therapies.